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Plague is one of the most dangerous infections in humans caused by Yersinia pestis,
a Gram-negative bacterium. Despite of an overwhelming research success, no ideal
vaccine against plague is available yet. It is well established that F1/LcrV based vaccine
requires a strong cellular immune response for complete protection against plague.
In our earlier study, we demonstrated that HSP70(II) of Mycobacterium tuberculosis
modulates the humoral and cellular immunity of F1/LcrV vaccine candidates individually
as well as in combinations in a mouse model. Here, we made two recombinant
constructs caf1–lcrV and caf1–lcrV–hsp70(II). The caf1 and lcrV genes of Y. pestis and
hsp70 domain II of M. tuberculosis were amplified by polymerase chain reaction. Both
the recombinant constructs caf1–lcrV and caf1–lcrV–hsp70(II) were cloned in pET28a
vector and expressed in Escherichia coli. The recombinant fusion proteins F1–LcrV and
F1–LcrV–HSP70(II) were purified using Ni-NTA columns and formulated with alum to
evaluate the humoral and cell mediated immune responses in mice. The protective
efficacies of F1–LcrV and F1–LcrV–HSP70(II) were determined following challenge of
immunized mice with 100 LD50 of Y. pestis through intraperitoneal route. Significant
differences were noticed in the titers of IgG and it’s isotypes, i.e., IgG1, IgG2b, and IgG3
in anti- F1–LcrV–HSP70(II) sera in comparison to anti-F1–LcrV sera. Similarly, significant
differences were also noticed in the expression levels of IL-2, IFN-γ and TNF-α in
splenocytes of F1–LcrV–HSP(II) immunized mice in comparison to F1–LcrV. Both F1–
LcrV and F1–LcrV–HSP70(II) provided 100% protection. Our research findings suggest
that F1–LcrV fused with HSP70 domain II of M. tuberculosis significantly enhanced the
humoral and cellular immune responses in mouse model.
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INTRODUCTION
Yersinia pestis (Y. pestis), etiologic agent of plague is accountable for several outbreaks throughout
the world and caused the deaths of millions of people right through the history. In spite of
substantial advancement in its prevention and cure, ∼50,000 human cases of plague have been
reported during the last two decades (WHO, 2005). Worldwide, an average of 4000 human plague
cases are reported every year, with outbreaks erupting from time to time which cause mass
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casualties (Green et al., 2014). Therefore, now, World Health
Organization (WHO) considered plague as a re-emerging disease
(Schrag and Wiener, 1995; WHO, 2005).
Humans are very prone to plague infection and the etiology
of the infection is reliant to the route and source of the
infection, consequential in one of the three main clinical forms
of plague: bubonic, septicaemic, and pneumonic (Williamson,
2009). Transmission of Y. pestis bacilli to a human begins
with an accidental bite of an infected flea and causing the
bubonic plague. Y. pestis occasionally reaches to the lungs or
inhalation of aerosolized Y. pestis follow-on pneumonic plague.
This pneumonic form of plague has the highest fatality rate with
a 1–3 days incubation period. This pneumopathy is 100% lethal
usually less than 3 days if no treatment is provided (Butler, 2013).
The possible use of aerosolized Y. pestis as a bio-weapon
agent is also a serious risk due to its high fatality rate and
transmission of human-to-human capability. Centers for Disease
Control (CDC) has classified to Y. pestis in a category of biosafety
level-3 (BSL-3) organisms. There are antibiotics available for the
treatment of plague but recently antibiotic resistant plague bacilli
have been reported (Galimand et al., 1997; Guiyoule et al., 2001).
It is documented that antibiotic resistant strains of Y. pestis can
be prepared in laboratory by transferring the plasmids containing
antibiotic resistance genes (Guiyoule et al., 2001; Chain et al.,
2004). Therefore, antibiotics are likely to be less effective in the
future against intentional/natural outbreaks of plague. In such
a scenario, vaccines may be one of the only left over options to
control the fatality toll in humans. Therefore, it is imperative to
develop an effective and safe plague vaccine.
Currently, there is no licensed vaccine available against plague.
Earlier, the strain EV76 of Y. pestis (live attenuated) was used
and confers protection in humans (Girard, 1963; Feodorova
and Motin, 2011). However, Y. pestis has been considered a
major obstacle in its use as live attenuated or killed vaccine due
to its genetic instability and several risk factors (side effects)
associated with it (Chain et al., 2004; Cui et al., 2014). Recently,
many recombinant protein based vaccines candidates have been
developed; amongst them only two vaccines, i.e., RypVaxTM and
rF1VTM are the most superior in clinical trials. These vaccines
mainly rely on a combination of two proteins, F1 and LcrV
(Williamson et al., 1995; Heath et al., 1998). These two antigens
F1 and LcrV are the main and effective targets which provide
protective immunity against plague (Burrows, 1956; Girard,
1963). Recombinant vaccine candidates are generally formulated
with aluminum hydroxide gel, a human compatible adjuvant and
thus are strong inducers of humoral immune response but poor
inducers of cellular immunity (Mannhalter et al., 1985; Dinc
et al., 2014). The cellular immune response, however, plays an
important role to develop protective immunity against plague
(Smiley, 2008). Despite of adequate humoral immune response,
F1–V-based vaccines provide poor and inconsistence protection
in African Green monkeys, probably due to a weak cellular
immune response.
In our earlier studies (Batra et al., 2014), we have shown that
F1 and LcrV in formulation with HSP70(II) of M. tuberculosis
induced an improved cellular immune response in mouse model.
HSP70(II) modulated the cell mediated immunity as there was a
significant difference in the expression of IFN-γ and TNF-α in
mice immunized with a cocktail of F1, LcrV, and HSP70(II) in
comparison to mice immunized with F1+LcrV. In continuation
to our efforts to develop a more effective vaccine against
plague, here we made two recombinant constructs caf1–lcrV
and caf1–lcrV–hsp70(II) successfully expressed in Escherichia
coli and purified the recombinants proteins by metal affinity
chromatography upto homogeneity. To evaluate the protective
potential and immune responses, Balb/C mice were immunized
with F1–LcrV and F1–LcrV–HSP70(II). There was a significant
difference in IgG response in the sera of immunized mice with
F1–LcrV–HSP70(II) in comparison to F1–LcrV. The F1–LcrV–
HSP70(II) induced significantly elevated levels of IL-2, IFN-γ,
TNF-α in comparison to F1–LcrV vaccine candidate. Immunized
mice were experimentally infected with 100 LD50 of Y. pestis (S1
strain) via intra-peritoneal route.
MATERIALS AND METHODS
Ethics Statement
All the protocols for conducted experiments using mice approved
by Institutional Animal Ethics Committee (IAEC) of Defence
Research and Development Establishment via registration
number 37/Go/C/1999/CPCSEA. All the procedures of good
laboratory animal care were followed during the course of
experiment. The experimental mice were maintained according
to the recommendations of committee for the purpose of control
and supervision of experiments on animals (CPCSEA), Govt. of
India.
Bacterial Strains, Plasmids, and
Reagents
Escherichia coli host strain BL21 (DE3) and DH5α were
purchased from Invitrogen, USA. Y. pestis (S1 strain), an
Indian clinical isolate (Verma et al., 2013; Batra et al., 2014)
was collected from DRDE repository (DB182YEPE1) used for
challenge experiments. The expression vector pET28a+was from
Novagen, USA. Live Y. pestis cultures and challenge experiments
were completed in high containment facility (BSL-3), at DRDE,
Gwalior.
Cloning of caf1–lcrV and
caf1–lcrV–hsp70(II) Recombinant
Constructs in pET Vector
Yersinia pestis cultures were grown on Brain Heart Infusion
(BHI) agar plate and incubated at 28◦C for 48 h. Genomic
DNA was extracted by DNeasy Blood and Tissue kit (Qiagen,
Germany) according to the manufacturer’s instruction. The
genes caf1 and lcrV of Y. pestis were amplified by polymerase
chain reaction (PCR). The gene hsp70(II) of M. tuberculosis was
amplified by PCR from an earlier cloned plasmid (Batra et al.,
2014). The descriptions of used primers are given in Table 1.
To prepare the caf1–lcrV construct, first caf1 was ligated with
pET28a vector using Nco I and Bam HI and later lcrV ligated
in the same plasmid using BamHI and Sal I restriction enzymes.
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TABLE 1 | List of oligos.
Gene Oligos Restriction sites Size (bp)
caf1 F-5′-ataccatgggcATGAAAAAAATCAGTTCCGTTATCG-3′ Nco I 513
R-5′-taggatccTTGGTTAGATACGGTTACGGTTACAG-3′ Bam HI
lcrV F-5′-taggatccATTAGAGCCTACGAACAAAACCCACA-3′ Bam HI 981
R-5′-tagtcgacTTTACCAGACGTGTCATCTAGCAGACG-3′ Sal I
R′-5′-tagagctcTTTACCAGACGTGTCATCTAGCAGACG-3′ Sac I
hsp70(II) F-5′-tagagctcGAGAAGGAGCAGCGAATCCTG-3′ Sac I 630
R-5′-taaagcttCGGGGTAACATCAAGCAGCAG-3′ Hind III
Similarly, in order to prepare the caf1–lcrV–hsp70(II) construct,
lcrV reverse primer (R) was replaced with reverse primer (R′)
that carrying the Sac I restriction site. First caf1 was ligated with
pET28a vector using the same restriction enzymes as mentioned
above followed by lcrV using Bam HI and Sac I followed by
hsp70(II) using Sac I and Hind III restriction enzymes. These two
ligated constructs were transformed in DH5α cells and positive
clones were selected using kanamycin (50 µg/ml).
Expression and Purification of F1–LcrV
and F1–LcrV–HSP70(II)
The individual recombinant construct corresponding to caf1–
lcrV and caf1–lcrV–hsp70(II) cloned in pET28a vector was
transformed in BL21(DE3) cells. The positive colonies were
selected on Luria-Bertani (LB) agar plates using kanamycin
(50 µg/ml). The single colony of each construct, i.e., caf1–
lcrV and caf1–lcrV–hsp70(II) was inoculated individually into
5 ml of LB broth and grown at 37◦C for overnight. Next
day, 500 ml of LB broth was inoculated with 1% of overnight
grown culture and incubated at 37◦C. When the optical density
(OD600) reached upto ∼0.6, the cultures were induced with
1 mM isopropylthiogalactoside (IPTG) and grown for 4 h at
37◦C. The cultures were pelleted by centrifugation at 10,000 × g
for 10 min at 4◦C. The cells were lysed in sample buffer and
analyzed by SDS–PAGE for the expression. The recombinant
fusion proteins F1–LcrV and F1–LcrV–HSP70(II) were purified
using 8 M urea by metal affinity chromatography using Ni-
NTA columns (Qiagen, USA). The purified antigens were run
on 10% SDS–PAGE and anti-histidine tag antibodies (Qiagen,
USA) recognized both recombinant proteins in Western blot
experiments. The purified proteins were subjected under dialysis.
The dialyzed proteins were concentrated using Amicon ultra
centrifugal filter devices (Millipore). Protein concentrations were
measured by BCA method using BCA kit (Sigma, USA).
Immunization of Mice
In order to test the protective efficacy and immune responses
of F1–LcrV and F1–LcrV–HSP70(II) vaccine candidates against
Y. pestis, female Balb/C mice (6 week old) were collected from
DRDE animal facility, Gwalior. The animals were divided in two
batches; each batch was containing three groups (8 mice/group),
i.e., Control group; F1–LcrV group; and F1–LcrV–HSP70(II)
group (Figure 3A). Batch-I was utilized for the study of humoral
immune response (IgG antibody) and challenge experiments
against Y. pestis. Batch-II was utilized for the study of cell
mediated immune response (cytokine profiling). Animals were
immunized subcutaneously with 20 µg/mouse of each purified
protein in formulation with aluminum hydroxide gel. The
animals of control group received PBS only. The immunizations
were given on day 0; day 14; and day 21. All the immunized
animals were subjected for blood collection on day 0, 21, and 28 as
shown in Figure 3B. Sera were separated from the blood samples
for the study of humoral immune response and IgG isotyping.
IgG Antibody Response
The end point titers of IgG antibodies were measured by
enzyme-linked immunosorbent assay (ELISA) in the sera of
immunized and control group animals. In brief, 96 well ELISA
plates were coated individually with F1–LcrV and F1–LcrV–
HSP70(II) fusion proteins using 100 ng/well each antigen in
0.05 M carbonate buffer, pH 9.6. The coated plates were incubated
for overnight at 4◦C. After three extensive washings with 0.05%
Tween 20 in PBS (PBS-T), the plates were blocked with 3% bovine
serum albumin (BSA), incubated for 2 h at 37◦C. Plates were
washed, test sera collected from immunized and control groups
after first and second boosters were serially diluted in triplicate
wells (100 µl/well). The plates were incubated for 1 h at 37◦C.
After five extensive washings, plates were probed with anti-mouse
horseradish peroxidase (HRP) labeled IgG (Sigma, USA) raised
in rabbit at 1:20,000 dilutions in PBS, incubated for 1 h at 37◦C.
The plates were washed as earlier and the reaction was developed
with o-phenylenediamine dihydrochloride as substrate and after
10 min stopped by 2N H2SO4. The optical density (OD) was
measured at 490 nm by a multimode reader (Biotek, USA).
IgG Isotyping
In order to characterize the IgG isotypes, microtiter plates
were coated with F1–LcrV and F1–LcrV–HSP70(II) (0.1 µg/
well) and blocked with BSA as mentioned above. IgG isotypes
sera from animal groups viz; control, F1–LcrV and F1–LcrV–
HSP70(II) collected after second booster, added at 1:1000 dilution
in PBS in triplicate wells. Plates were incubated for 1 h at
37◦C, washed and again incubated with goat anti-mouse isotype
specific antibodies IgG1, IgG2a, IgG2b, and IgG3 (Sigma, USA)
at 1:1000 dilutions for 1 h at 37◦C. Detection of bound isotype
specific antibodies was estimated with rabbit anti-goat IgG
HRP conjugated (1:5000 dilutions). The reaction was stopped
with 2N H2SO4 and optical density (OD) was measured at
490 nm.
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Cellular Immune Response
Animal groups of batch-II were sacrificed and their spleens
were removed in aseptic conditions. To measure the cytokines
single cell suspension of spleen cells was prepared. The cells
(1 × 106 cells/well) of each group were seeded in triplicates
in a culture plate. The cells were stimulated with F1–LcrV or
F1–LcrV–HSP70(II) antigens or ConA (5 µg/ml each). After
48 h, the supernatants of cultured spleen cells were collected.
The induced level of IL-2; IL-4; IL-10; IFN-γ; and TNF-α were
estimated by ELISA kit (BD Biosciences, USA) according to the
manufacturer’s instructions. The concentrations of cytokines in
picograms per milliliter (pg/ml) were measured with the help of
standard curves using recombinant cytokines as standard with
the ELISA kit.
Challenge of Animals
Yersinia pestis (S1 strain) from the frozen stocks were streaked
on BHI agar plate and incubated at 28◦C for 48 h. Single colony
from BHI agar plate was further inoculated in 5 ml of BHI
broth and grown at 28◦C for 48 h. The LD50 of Y. pestis (S1
strain, an Indian clinical isolate) has been determined earlier
(Verma et al., 2013; Batra et al., 2014). To determine the
protective potential of F1–LcrV and F1–LcrV–HSP70(II) vaccine
candidates, animals of batch-I were infected with 100 LD50 of
Y. pestis via intraperitoneal route after 1 month of last booster.
Infected animals were observed for their survival for 30 days of
challenge (Figure 3A).
Statistical Analysis
Results were presented as the means value ± standard deviation
(SD). Statistical comparisons among various immunized groups
were analyzed by SigmaStat 3.5, one way ANOVA, All
Pairwise Multiple Comparison Procedure (Fisher LSD Method).
∗P < 0.05; ∗∗P < 0.01; ∗∗∗P < 0.001; #P < 0.001. Survival curves
were prepared by Kaplan–Meier method using GraphPad Prism
6.0 demo version (∗∗∗∗P < 0.0001).
RESULTS
Cloning of caf1–lcrV and
caf1–lcrV–hsp70(II) in pET Vector
In order to prepare F1–LcrV and F1–LcrV–HSP70(II) proteins,
caf1 of 513 bp and lcrV 981 bp of Y. pestis and hsp70(II) of
FIGURE 1 | (A) PCR amplification of caf1 and lcrV genes of Yersinia pestis & cloning of caf1–lcrV in pET vector. caf1 gene (a); Lane 1, 1Kb DNA ladder; Lane 2, caf1
gene product of 513 bp. lcrV gene (b); Lane 1, 1Kb DNA ladder; Lane 2, lcrV gene product of 981 bp. Screening of positive clones of caf1–lcrV fusion product after
ligation in pET28a vector (c); Lane 1, 1 Kb DNA ladder; Lane 2–4, released inserts (caf1–lcrV ) of ∼1500 bp after restriction digestion from pET vector. (B)
Recombinant F1–LcrV fusion protein expression profile and purification. (a) SDS–PAGE analysis of F1–LcrV protein expression. Lane 1, Pre-stained protein marker;
Lane 2, Uninduced Escherichia coli cell lysate clone; Lane 3, Induced E. coli cell lysate (b) Western blot analysis of F1–LcrV protein showing reaction with anti HIS
antibody. Lane 1, Pre-stained protein marker; Lane 2, Uninduced E. coli cell lysate clone; Lane 3, Induced E. coli cell lysate. (c) Purification of F1–LcrV protein. Lane
1, Protein marker; Lane 2, Cell lysate; Lane 3, Flow through; Lane 4, Wash; Lane 5–10, Eluted fractions of protein showing F1–LcrV protein of 54 kDa.
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FIGURE 2 | (A) PCR amplification of caf1, lcrV genes of Y. pestis and hsp70(II) of Mycobacterium tuberculosis & cloning of caf1–lcrV–hsp70(II) in pET vector. caf1
gene (a); Lane 1, 1 Kb DNA ladder; Lane 2, caf1 gene product of 513 bp: lcrV gene (b); Lane 1, 1 Kb DNA ladder; Lane 2, lcrV gene product of 981 bp: hsp70(II)
gene (c); Lane 1, 1 Kb DNA ladder; Lane 2, hsp70(II) gene product of 630 bp. Screening of positive clones of caf1–lcrV–hsp70(II) fusion product after ligation in
pET28a vector (d); Lane 1, 1 Kb DNA ladder; Lane 2–4, released inserts (caf1–lcrV ) of 2124 bp after restriction digestion from pET vector. (B) Recombinant
F1–LcrV-HSP70(II) trivalent fusion protein expression profile & purification. (a) SDS–PAGE analysis of F1–LcrV–HSP70(II) protein expression: Lane 1, Protein marker;
Lane 2, Uninduced E. coli cell lysate clone; Lane 3, Induced E. coli cell lysate. (b) Purification of F1–LcrV–HSP70(II) protein: Lane 1, Protein markers; Lane 2, Cell
lysate; Lane 3, Flow through; Lane 4, Wash; Lane 5–10, Eluted fractions of purified protein showing F1–LcrV–HSP70(II) fusion protein of 79 kDa. (c) Western blot
analysis of purified F1–LcrV–HSP70(II) protein showing reaction with anti HIS antibody: Lane 1, Pre-stained protein marker; Lane 2, purified F1–LcrV–HSP70(II)
protein.
FIGURE 3 | Representation of animal groups and the schedule of vaccination activities. (A) Prepared groups of Balb/C mice (8/group) for vaccination
studies with F1–LcrV and F1–LcrV–HSP70(II) in formulation with alum. (B) Schematic representation of vaccination schedule, blood collection for humoral and cell
mediated studies and challenge experiments.
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FIGURE 4 | End point titers of IgG antibody and IgG isotypes in the
sera of immunized mice. (A) IgG end point titers were estimated by ELISA.
Serum samples were collected after first and second boosters from
vaccinated animal groups, i.e., F1–LcrV and F1–LcrV–HSP70(II)). (B) The IgG
isotypes; IgG1, IgG2a, IgG2b, and IgG3 were measured by ELISA. End point
titers of IgG isotypes in sera samples collected after second booster from
vaccinated mice with F1–LcrV and F1–LcrV–HSP70(II) antigens. Analysis was
done by one way ANOVA, all Pairwise Multiple Comparison Procedure (Fisher
LSD Method). ∗∗ P < 0.01; ∗∗∗ P < 0.001; #P < 0.001.
M. tuberculosis were amplified by PCR (Figures 1 and 2) with
the help of primers manipulated with compatible restriction
site (Table 1). First, caf1 and lcrV were linked with help
of Bam HI restriction enzymes (Figure 1A(c)). The caf1–
lcrV construct was carrying NcoI and Sal I restriction sites
at 3′ and 5′, respectively. Similarly, to prepare the caf1–lcrV–
hsp70(II), caf1, lcrV, and hsp70(II) were linked with help of
Bam HI and Sac I restriction sites (Figure 2A(d)). The caf1–
lcrV–hsp70(II) construct was carrying Nco I and Hind III
restriction sites at 3′ and 5′, respectively. The DNA constructs,
caf1–lcrV of ∼1500 bp encoding F1–LcrV a bivalent protein
(∼54 kDa) and caf1–lcrV–hsp70(II) of ∼2130 bp encoding F1–
LcrV–HSP70(II) a trivalent protein (∼79 kDa) were cloned
in pET28a+ vector using Nco I/Sal I and Nco I/Hind III
restriction sites. The individual pET vector carrying the caf1–
lcrV and caf1–lcrV–hsp70(II) was transformed in DH5α cells
and the positive clones were selected on LB agar plates
with kanamycin. The in-frames of the cloned constructs
FIGURE 5 | Estimation of cytokines in vaccinated animal groups.
Splenocytes isolated from immunized BALB/c mice with F1–LcrV and
F1–LcrV–HSP70(II) including control group. Splenocytes were stimulated with
F1–LcrV and F1–LcrV–HSP70(II) antigens (5 µg/ml each) and after 48 h, the
expression levels of cytokines were measured. The expression levels of
cytokines (A) IL-2, (B) IFN-γ, and (C) TNF-α were calculated in picograms per
milliliter (pg/ml) as shown in graphs. Data represent the average of 8
mice/group ± SD of the results determined. One way ANOVA was applied for
analysis. ∗∗∗ P < 0.001; #P < 0.001.
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FIGURE 6 | Vaccination with F1–LcrV and F1–LcrV–HSP70(II) protects
mice against Y. pestis (S1 strain). The vaccinated and control group
animals were experimentally infected via i.p. route with 100 LD50 of virulent
Y. pestis. The survivals of animals were monitored for 30 days after challenge.
The survival curve of both the vaccine candidates F1–LcrV and
F1–LcrV–HSP70(II) was determined by Kaplan Meier’s method to calculate
percentage survivals (∗∗∗∗ P < 0.0001).
were validated by nucleotide sequencing (Chromous Biotech,
India).
Expression and Purification of F1–LcrV
and F1–LcrV–HSP70(II)
One of the positive clones corresponding to caf1–lcrV and
caf1–lcrV–hsp70(II) was individually transformed in E. coli host
BL-21 (DE3). For the expression of F1–LcrV and F1–LcrV–
HSP70(II), 500 ml LB broth was inoculated to each clone and
the cultures were induced with IPTG. The expressed proteins
F1–LcrV and F1–LcrV–HSP70(II) were analyzed by SDS–PAGE.
The proteins SDS–PAGE profiles of un-induced and IPTG-
induced cultures for F1–LcrV and F1–LcrV–HSP70(II) are
shown in Figures 1B(a) and 2B(a), respectively. In Western
blot experiments, anti-histidine antibody recognized F1–LcrV
and F1–LcrV–HSP70(II) protein bands corresponding to their
molecular weights as shown in Figures 1B(b) and 2B(c). In
order to purify the fusion proteins, i.e., F1–LcrV and F1–
LcrV–HSP70(II), the recombinant constructs were engineered
to bear the 6X-Histine tag at C-terminus. Both the cultures
were lysed using native conditions and both the proteins were
found present in pellet fractions. The purification was carried out
under denaturing conditions by solubilizing the pellet of each
culture separately in 8 M urea. Both the proteins were purified
by Ni-NTA affinity chromatography using earlier published
protocol (Verma et al., 2013). The purified F1–LcrV and F1–
LcrV–HSP70(II) proteins were analyzed by SDS–PAGE as shown
in Figures1B(c) and 2B(b), respectively. Both purified proteins
were concentrated and the obtained yield of F1–LcrV and F1–
LcrV–HSP70(II) was 2.0 and 2.5 mg/L of shake flask cultures,
respectively.
IgG Antibody Response
To measure the IgG endpoint titers, sera were collected 7 days
after first and second injections, respectively, from all the
immunized animals as shown Figure 3B. The cut-off value for
the assays was calculated as the mean OD (+2 SD) from sera
of control group assayed at 1:200 dilutions. The IgG endpoint
titers were calculated as reciprocal of the highest serum dilution
giving an OD more than the cut-off. The IgG endpoint titer to
F1–LcrV was observed 1.28 × 105 and 2.56 × 105 in the sera
of F1–LcrV group after first and second booster, respectively.
The IgG endpoint titer to F1–LcrV–HSP70(II) was observed
2.56 × 105 and 5.12 × 105 in the sera of F1–LcrV–HSP70(II)
group after first and second booster, respectively. A significant
difference (#P < 0.001) was observed in the endpoint titer of
F1–LcrV–HSP70(II) immunized sera in comparison to F1–LcrV
immunized sera (Figure 4A).
IgG Isotypes
The endpoint titers of IgG isotypes were also determined
similarly as described above. IgG isotypes were measured by
ELISA specific to F1–LcrV and F1–LcrV–HSP70(II) in sera
samples collected after 7 days of second boosters from all the
immunized groups. Significantly elevated levels of IgG1, IgG2b
and IgG3 were observed to F1–LcrV–HSP70(II) (Figure 4B) in
comparison to F1–LcrV group whereas; there was no difference
in the expression of IgG2b to both the groups.
Cellular Immune Response
The expression levels of cytokines, i.e., IL-2, IL-4, IL-10, IFN-γ,
and TNF-α of all immunized animal groups were measured in
supernatants of splenocytes stimulated with required antigen/s.
A significance difference (∗∗∗P < 0.001) was noticed in the
expression levels of IL-2 (Figure 5A), IFN-γ (Figure 5B),
and TNF-α (Figure 5C) in F1–LcrV and F1–LcrV–HSP70(II)
immunized animal groups in comparison to control group. There
was no significant difference in the expression levels of IL-4
and IL-10 (data not shown). The splenocytes from all animal
groups were induced with ConA and responded non-specifically.
We also observed a significant difference (#P < 0.001) in the
expression of IL-2, IFN-γ and TNF-α in F1–LcrV–HSP70(II)
immunized group in comparison to F1–LcrV group.
Protection Studies
To study the protective efficacy, the immunized animals were
challenged with 100 LD50 of Y. pestis (S1 strain) including control
group. Survivals of the animals were monitored for 30 days post
challenge (Figure 6). Both vaccine candidates F1–LcrV and F1–
LcrV–HSP70(II) provided 100% protection from the Y. pestis
challenged mice (∗∗∗∗P < 0.0001). There was no protection
observed in control groups.
DISCUSSION
Plague is a historic and lethal infectious disease which is so
far prevalent in many regions of the recent world and caused
by Y. pestis, a potential bio-warfare agent. After the attacks of
anthrax in 2001 in USA, it became preferential to stockpile the
safe and ideal vaccines against anthrax and plague to protect
a mass population against these deadly dangerous bioterror
attacks. Nevertheless, there is no plague vaccine has been
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approved worldwide so far. The possible explanations comprise
inconsistence protection, weak stability, poor immunogenicity
and the problems in formulation strategies. Modern antigens
designing strategies and new vaccine proposals will be helpful
to conquer these problems. These new strategies would be of
immense attention to develop an effective plague vaccine. In this
study, we generated a new trivalent fusion protein that provided
full protection against plague in a mouse model.
The F1, a capsular protein and LcrV, a type III secretion
protein are the surface-exposed antigens of Y. pestis and
have been the leading antigens to develop a subunit vaccine
against plague for many years (Anderson et al., 1998; Heath
et al., 1998; Williamson, 2009). The vaccine based on these
two candidates (F1/LcrV) is poorly immunogenic and mainly
induces humoral immune response. Despite of generating high
titers of anti-F1/LcrV specific IgG antibodies, some vaccinated
animals succumbed to challenge (Bashaw et al., 2007). The
protection conferred by live attenuated Salmonella expressing
LcrV antigen in mouse model did not show any correlation
with LcrV antibody titers (Garmory et al., 2003). Similarly,
vaccination of non-human primates specially, African Green
monkeys with recombinant F1–LcrV fusion protein impart
partial and inconsistent protection against plague and the level of
protection did not correlate with the generated humoral immune
response either F1 or LcrV antibody titers (Bashaw et al., 2007;
Rosenzweig et al., 2011; Williamson and Oyston, 2013). These
conclusions, strongly advocate that antibodies titers alone cannot
sufficiently envisage the efficacy of F1/LcrV based vaccines.
In order to improve the efficacy of F1/LcrV-based vaccines,
several approaches were undertaken like genetic modification
of the antigens, e.g., by mutating cysteine amino acid in rF1/V
(Goodin et al., 2007) or by deleting the immunosuppressive
region of LcrV (DeBord et al., 2006), use of alternate adjuvants
like alum, poly-L-lactide microspheres, Monophosphoryl lipids,
TiterMax, and flagellin as an molecular adjuvant (Honko et al.,
2006; Jones et al., 2006; Feodorova and Motin, 2012), delivery
platforms (Garmory et al., 2003; Palin et al., 2007; Yang et al.,
2007) and formulations with additional antigen/s that might play
the role of an immunomodulator/s or an immunoregulator/s to
enhance the immune response.
Heat shock proteins (HSPs) are best known to modulate
the immune response (Hauser and Chen, 2003; Pockley, 2003;
Robert, 2003; Binder, 2006) and stimulating effective T-cell
responses to model antigens (Rico et al., 1998) and pathogen-
derived antigens as well (Chen et al., 2000; Huang et al.,
2000). Recently, domain II of heat shock protein, HSP70(II)
of M. tuberculosis has been proven for inducing the T-cell
response by many scientists (Massa et al., 2005; Dhakal et al.,
2013). Recombinant fusion constructs Ovalbumin-HSP70(II)
elicit CD8+ cytotoxic T lymphocytes specific to ovalbumin
(Huang et al., 2000). Suzue and Young (1996) proved that
HSP70(II) of M. tuberculosis augment the humoral and cellular
immune response to the p24 protein of HIV-1. Subsequently,
Wang et al. (2002), reported that the C-terminal portion (amino
acids 359–610) of the mHSP70 mainly elicits Th-1 type of
cytokines (IL-2, TNF-α, and IFN-γ) and higher serum IgG2a and
IgG3 isotypes of antibodies.
In our earlier studies (Batra et al., 2014), we have characterized
heat shock protein 70 domain II, HSP70(II) of M. tuberculosis
as an immunomodulator to augment the immune response
of F1 and LcrV vaccine candidates. It has been proven in
our earlier studies that HSP70(II) not only enhances the
protective efficacy of F1 and LcrV but also modulates the cellular
immune responses and significantly increases the expression
levels of IL-2, IFN-γ, and TNF-α in mouse model. HSP70(II)
significantly increased the IFN-γ secreting CD4+ and CD8+
T cells in the mice immunized with a cocktail of F1, LcrV,
and HSP70(II) comparison to mice immunized with F1and
LcrV. In the present study to reduce the labor, cost, and
time, for generation of individual protein, we made two fusion
constructs, F1–LcrV and F1–LcrV–HSP70(II) and evaluated
in mice. We were able to demonstrate that fusion construct
of F1–LcrV–HSP70(II) could provide a significant increase
in the production of IgG antibody in comparison to F1–
LcrV. A significant difference was also noticed in the titers
of IgG isotypes, i.e., IgG1, IgG2b, and IgG3 in F1–LcrV–
HSP70(II) vaccinated group in comparison to F1–LcrV. We
also noticed the significant difference in the expression of IL-
2, IFN-γ and TNF-α by the splenocytes in F1–LcrV–HSP70(II)
immunized animal group in comparison to F1–LcrV. Both
recombinant fusion proteins F1–LcrV and F1–LcrV–HSP70(II)
provided full protection against virulent Y. pestis in a mouse
model. The results generated with these two fusion proteins
were in agreement with our earlier findings (Batra et al.,
2014).
CONCLUSION
The study is worthwhile as the fusion of HSP70(II) with
F1–LcrV significantly enhanced the humoral (IgG and its
isotypes; IgG1, IgG2b, and IgG3) and cellular (IL-2, IFN-
γ, and TNF-α) immune responses. These research findings
open up new avenues for vaccine development against plague,
however, the findings further need to be evaluated in non-human
primates.
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